| Autor: |
Livio Pagano, Marianna Criscuolo, Alessandro Broccoli, Alfonso Piciocchi, Marzia Varettoni, Eugenio Galli, Antonella Anastasia, Maria Cantonetti, Livio Trentin, Sofia Kovalchuk, Lorella Orsucci, Annamaria Frustaci, Angelica Spolzino, Stefano Volpetti, Ombretta Annibali, Sergio Storti, Caterina Stelitano, Francesco Marchesi, Massimo Offidani, Beatrice Casadei, Maria Elena Nizzoli, Maria Lucia De Luca, Luana Fianchi, Marina Motta, Luca Guarnera, Edoardo Simonetti, Andrea Visentin, Francesco Vassallo, Marina Deodato, Chiara Sarlo, Attilio Olivieri, Brunangelo Falini, Alessandro Pulsoni, Enrico Tiacci, Pier Luigi Zinzani |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Blood Cancer Journal, Vol 12, Iss 7, Pp 1-8 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2044-5385 |
| DOI: |
10.1038/s41408-022-00702-9 |
| Popis: |
Abstract Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), although relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data of HCL patients treated with 2CDA between March 1991 and May 2019 at 18 Italian Hematological centers: 513 patients were evaluable for study purpose. The median age was 54 years (range 24–88) and ECOG was 0 in 84.9% of cases. A total of 330 (64.3%) patients received 2CDA intravenously and 183 (35.7%) subcutaneously. ORR was 91.8%: CR was obtained in 335 patients (65.3%), PR in 96 (18.7%), and hematological response in 40 (7.8%) patients; in 42 (8.2%) no response was observed. Hemoglobin value (p = 0.044), frequency of circulating hairy cells (p = 0.039), recovery of absolute neutrophil count (p = 0.006), and normalization of spleen (p ≤ 0.001) were associated with CR compared to PR in univariable analysis. At a median follow-up of 6.83 years (range 0.04–28.52), the median time to relapse was 12.2 years. A significant difference in duration of response was identified between patients that obtained a CR and PR (19.4 years versus 4.8 years, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink